title: Efficacy and safety of antifungals in pediatric patients.
abstract: Invasive fungal infections (IFIs) constitute an important cause for morbidity and mortality in immunocompromised pediatric patients [1]. Despite substantial achievements, the prevention and treatment of IFIs are still limited by the facts that not all antifungal agents are approved in the pediatric population, the appropriate dosage of these drugs has not been established for all age groups, and postmarketing data providing information on the safety and efficacy of approved agents under real-life circumstances are scant. In this article, we 1) briefly review the principles of drug development, 2) discuss safety and approved indications of antifungal agents, and 3) provide a summary of current options for treatment of invasive fungal infections in pediatric patient populations.
authors.affiliation: Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology, University Children's Hospital, Muenster, Germany. grollan@ukmuenster.de
authors.forename: Andreas H
authors.initials: AH
authors.lastname: Groll
mesh_terms: D000935:Antifungal Agents / Q000009:adverse effects* / Q000138:chemical synthesis / Q000627:therapeutic use*; D002648:Child; D015195:Drug Design; D006801:Humans; D016867:Immunocompromised Host; D008954:Models, Biological; D010372:Pediatrics / Q000379:methods*; D011315:Preventive Medicine / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents